Trial Profile

A Phase Ib/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Recommended Combination Dose of BNT324 With BNT327 in Participants With Advanced Lung Cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 28 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elfetabart drozuntecan (Primary) ; Pumitamig (Primary)
Indications Liver cancer; Malignant-mesothelioma; Neuroendocrine tumours; Non-small cell lung cancer; Small cell lung cancer; Solid tumours; Triple negative breast cancer
Focus Adverse reactions; Proof of concept; Therapeutic Use
Sponsors BioNTech

20 Aug 2026 According to BioNTech media release, the data from the trial will be presented at the IASLC 2026 World Conference on Lung Cancer (WCLC).
24 Jun 2026 Planned End Date changed from 1 Jun 2031 to 1 May 2032.
24 Jun 2026 Planned primary completion date changed from 1 Aug 2027 to 1 Sep 2028.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com